304 related articles for article (PubMed ID: 25640331)
1. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
2. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
[TBL] [Abstract][Full Text] [Related]
3. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
5. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
6. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
7. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast-specific Krm2 overexpression and Lrp5 deficiency have different effects on fracture healing in mice.
Liedert A; Röntgen V; Schinke T; Benisch P; Ebert R; Jakob F; Klein-Hitpass L; Lennerz JK; Amling M; Ignatius A
PLoS One; 2014; 9(7):e103250. PubMed ID: 25061805
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
10. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
11. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
12. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
[TBL] [Abstract][Full Text] [Related]
13. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.
Riddle RC; Diegel CR; Leslie JM; Van Koevering KK; Faugere MC; Clemens TL; Williams BO
PLoS One; 2013; 8(5):e63323. PubMed ID: 23675479
[TBL] [Abstract][Full Text] [Related]
14. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
15. The high bone mass phenotype of Lrp5-mutant mice is not affected by megakaryocyte depletion.
Yorgan T; David JP; Amling M; Schinke T
Biochem Biophys Res Commun; 2018 Mar; 497(2):659-666. PubMed ID: 29454962
[TBL] [Abstract][Full Text] [Related]
16. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
17. Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand.
Luther J; Yorgan TA; Rolvien T; Ulsamer L; Koehne T; Liao N; Keller D; Vollersen N; Teufel S; Neven M; Peters S; Schweizer M; Trumpp A; Rosigkeit S; Bockamp E; Mundlos S; Kornak U; Oheim R; Amling M; Schinke T; David JP
Sci Transl Med; 2018 Nov; 10(466):. PubMed ID: 30404864
[No Abstract] [Full Text] [Related]
18. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
[TBL] [Abstract][Full Text] [Related]
19. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
20. N-cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage-Specific.
Fontana F; Hickman-Brecks CL; Salazar VS; Revollo L; Abou-Ezzi G; Grimston SK; Jeong SY; Watkins M; Fortunato M; Alippe Y; Link DC; Mbalaviele G; Civitelli R
J Bone Miner Res; 2017 Jun; 32(6):1332-1342. PubMed ID: 28240364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
